Amplia Therapeutics Limited (ASX: ATX) is an Australian, publicly-listed, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.
Amplia’s pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading cancer and medicinal chemistry researchers at Australia’s top cancer research institutes. Amplia was established to advance these promising drugs into clinical development and commercialisation.
The first of these drugs, AMP945, is a highly selective and potent inhibitor of FAK and is clinical development for both pancreatic cancer Idiopathic Pulmonary Fibrosis (IPF). Orphan Drug Designations for both these indications have been granted by the US FDA.
In addition to AMP945, Amplia’s second pipeline drug, AMP886, also inhibits two key disease drug targets (VEGFR3 and FLT3) and is currently being evaluated in animal models of different cancers and fibrotic diseases.
Amplia’s Board and Management team includes some of Australia most seasoned and well-credentialled life-sciences executives who have extensive international experience in drug development, pharmaceuticals, and life-sciences deal-making.